Abstract
Introduction Individuals diagnosed with atherosclerotic cardiovascular disease (ASCVD), particularly those who have experienced acute coronary syndrome (ACS) within the past year, are at a heightened risk of recurrent cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) levels has been proven effective in reducing this risk. However, there is a lack of a comprehensive meta-analysis investigating the LDL-C-lowering effectiveness and coronary atherosclerotic plaque compositions of Ezetimibe. This study aims to address this gap in knowledge.
Methods We conducted a systematic review of randomized controlled trials that evaluated the LDL-C-lowering efficacy and coronary atherosclerotic plaques efficacy of ezetimibe in patients with ASCVD. We searched relevant databases, including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, for publications from database inception until Jul 2023. Meta-analyses were performed to assess the LDL-C-lowering and coronary atherosclerotic plaques efficacy of ezetimibe in the overall ASCVD population.
Results The meta-analysis included a total of 20 eligible studies. Our findings revealed that combination therapy of ezetimibe with statins resulted in a more substantial absolute reduction in LDL-C compared to statin monotherapy (mean difference of (−14.06 mg/dL; 95% confidence interval [CI] −18.0 to −10.0; p = 0.0001) after 6-12 months of treatment (or at a time point nearest to 6 -12months). Moreover, the subgroups analysis indicates that the intervention measures were effective in reducing the volume of fibro-fatty plaque (FFP) when compared to the control group [weighted mean difference (WMD) = -1.01, 95% confidence interval (CI) (-3.6 and 1.6), and p = 0.003], necrotic core (NC) volume [WMD =-5.41, 95% CI(-13.3 and 2.5), and p = 0.35], and change dense calcification (change DC) volume [WMD =-1.14, 95% CI (- 1.4 and – 0.8), and p = 0.62] between the treatment group and the control group.
Conclusions Our study indicates that the addition of ezetimibe to statin therapy results in a modest yet significant further reduction in LDL-C compared to statin monotherapy. Ezetimibe led to a significant reduction in FFP volume; however, there were no statistically significant differences observed for NC, or change DC volumes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
